Archive for the ‘Gene Therapy Research’ Category

Worlds Cutest Kittens (Tabby Kitten)
Meet my crazy cute tabby kittens! Gonzo and Caesar :p 🙂 I will be filming these funny kittens everyday as they grow from tiny kittens into cats! A tabby is any cat that has a distinctive coat that features stripes, dots, lines or swirling patterns, usually together with a mark resembling an "M" on its forehead. Tabbies are sometimes erroneously assumed to be a cat breed.[1] In fact, the tabby pattern is found in many breeds of cat, as well as among the general mixed-breed population. The tabby pattern is a naturally occurring feature that may be related to the coloration of the domestic cat #39;s direct ancestor, the African Wildcat, which (along with the European Wildcat and Asiatic Wildcat) has a similar coloration. In cat genetics, pattern is unrelated to color, and so the tabby coat pattern can show up in combination with a variety of coat colors, including tortoiseshell (Tortoiseshell Tabby cats are often called #39;Torbies #39;). A cat #39;s coat can be described as red tabby or gray tabby. Black and blue are colors that usually show up without tabby markings, but with some cats, a faint tabby pattern can actually be noticed. Bi-color cats can have the tabby pattern show up on the colored patches of their coat. For example, Tortoiseshell cats sometimes display a pattern where the red-based and black-based tortoiseshell pattern is mixed with tabby markings. White spotting of any level can also appear in combination with tabby patterns; however, white is the only coat color that ...From:whirlpoolhitmanViews:1 0ratingsTime:00:45More inPets Animals

Continued here:
Worlds Cutest Kittens (Tabby Kitten) - Video

2012 Indoor grow journal
little update on the grow. was heavily medicated as you will notice in my inaccurate numbers 45 degrees LOL. it was 84 at the time. Genetics are possibly known what i meant was sex. they are two jack the ripper bagseed and one unknown indica bagseed. then an unknown purple kush bagseed. in the back. 11/20/12 they got a their last trimming before flower and another feeding of bpn(blue planet nutrients) so far loving the product and 1/3rd of all the cost of other competitors. Also sorry for shit quality. Trying to find out why my video video turned it was fine before upload.From:bluestdream1Views:1 0ratingsTime:01:39More inPeople Blogs

Excerpt from:
2012 Indoor grow journal - Video

mutant genetica-dissolving web spider.....[23/10/2012,suffolk].
spider webs dont fucking dissolve,its that simple......so could this be genetic infection,or a genetic species made in a lab by the cut n splice genetic engineering brigade?...genetics is becoming such a plague,such a terrible mutation that.even god dont know anymore which species are natural......frankenfucks!From:ecliptyclunacyViews:5 1ratingsTime:03:01More inEducation

More here:
mutant genetica-dissolving web spider.....[23/10/2012,suffolk]. - Video

The turkduckhen of doom
The turkduckhen. Why eat turkey on thanksgiving when you can have turkduckhen. Made by a mad welder, he got everything right except the sense of direction. Which would be moderately fine, if he didn #39;t live on a blimp. animation made by Cobb Genetics of the Industries Incorporated Association club (copyright) made with Flip Boom Classic for MACFrom:WAMSonlineViews:3 0ratingsTime:00:31More inFilm Animation

Original post:
The turkduckhen of doom - Video

New Lifeform-Transhumanism
New Lifeform-Transhumanis In the first half of the show, the surprising scientific announcement about the discovery of an arsenic eating life form in Mono Lake, CA was discussed. After a brief report from Linda Moulton Howe, with audio from NASA astrobiologist Pamela Conrad, space researcher Robert Zimmerman joined the program. He characterized the Mono Lake microbe as an extremophile-- an organism that thrives in conditions that would be detrimental or impossible to survive for most other life forms. Also of interest was the journalistic hype that surrounded the pre-release of the story, he commented, with too much speculation and misinformation being spread by reporters. For more, see Zimmerman #39;s blog entry, When journalism runs wild. In the second hour, Richard C. Hoagland posed the question-- "Is it possible that this is an actual extraterrestrial life form which happened to find its right niche in Mono Lake after falling down from the skies?" He further suggested that today #39;s announcement could be part of NASA #39;s plan to lay out a foundation before declaring the existence of extraterrestrial life. --------------------- In the latter half of the show, researcher Tom Horn discussed the blistering pace of genetics and transhumanism, and how the technology could usher in a new genetic arms race. Over the last 2 years, statements by the Pentagon have described the "human enhancement revolution" as being right around the corner. He expressed concern over how biotech and ...From:DisclosureBubbleViews:0 0ratingsTime:02:32:11More inScience Technology

Continue reading here:
New Lifeform-Transhumanism - Video

Flip Out Vol 2 - Full Album (320kbps)
2002 - Flip Out Vol 2 - Mixed By Oforia (VA) Tracklist: 1. BLT - Genetics 2. GMS - Black Hole 3. Joti Sidhu - Downpusher 4. Kamasutrance vs Groove-A-Tech - Life Force 5. Electric Universe - Embrace It 6. Lemurians - Identification 7. Psydrop - Radical Command 8. Space Buddha - I Think Therefore I AmFrom:PsychedelicPowerViews:0 0ratingsTime:51:47More inMusic

See the rest here:
Flip Out Vol 2 - Full Album (320kbps) - Video

Cross Species Genetics Transhumanism
Thank You Chris HohnFrom:Pale BlueViews:0 0ratingsTime:14:59More inEducation

Here is the original post:
Cross Species Genetics

Colic Baby Relief | Remedies for Colic in newborns | Treatment for Colicky Babies
A colic baby is a newborn that suffers from an attack of crying from what appears to be intestinal pain. It is a fairly common condition and affects roughly 20% of babies. All infants cry when they are hungry, tired, hot or cold, or because of a dirty diaper. It is the only way for them to communicate their needs to us. Unfortunately, colicky babies also cry sometimes even after being cleaned, fed and warm cozy. Your may have a colic baby if he or she appears to be healthy but still suffers from frequent inconsolable crying. If this is the case, you need to seek relief for your loved one. Roughly 20% of newborns are colic babies. Most experts believe that it is not the result of genetics, pregnancy or childbirth issues. Some of the possible causes of a colicky baby are overstimulated senses, Infant acid reflux, immature digestive system (having difficulties digesting certain foods), food allergies/sensitivity and maternal smoking. This ailment is episodic. It can be irritated by improper diaper changing techniques, overfeeding and emotional stress. Doing research is always great but it is important that you consult a doctor to seek treatment if you suspect colic in a newborn. For more information, please visit: en.wikipedia.org Consoling and relieving a colic baby is difficult but there are remedies you can use to help. Here are a few treatments that may provide relief (but always talk to a pediatrician first). 1. Watch what you eat 2. Switch formulas 3. Consider ...From:ServiceFox1Views:0 0ratingsTime:03:41More inFilm Animation

More here:
Colic Baby Relief | Remedies for Colic in newborns | Treatment for Colicky Babies - Video

Value of plant genetics to the community
GUEST: Peter Davies - Plant Physiologist and US Department of State Science FellowFrom:ANCalertsViews:8 0ratingsTime:09:57More inNews Politics

Read more:
Value of plant genetics to the community - Video

Virtual Girl Girls Dancing Virtual Girls in Your Desktop
Virtual Girl Girls! virtualgirlgirls.com Axelle Parker Golden Eyes Origins: Antibes / France - Age: 19 Height: 5.51 - Weight: 110 - Vital Statistics: 35/24/35 Her unusual appearance is the result of interesting genetics. Axelle tells us that she is part Eskimo and part French. Not many women can say that, but if you look at the results, you #39;ll be wishing a lot more Frenchmen would start mixing with Eskimo women because the beauty that results from that genetic coupling is definitely something to smile about! Categories: Bikini, High Heels, Trimmed, Blonde, European Facebook! http://www.facebook.com Twitter! http://www.twitter.comFrom:alanscraigViews:0 0ratingsTime:01:58More inEntertainment

Read more:
Virtual Girl Girls Dancing Virtual Girls in Your Desktop - Video

Earnings momentum for Myriad Genetics (MYGN) has been on the rise ever since this molecular diagnostic company released strong fiscal first-quarter results earlier this month that included an upbeat guidance. Shares of this Zacks #1 Rank (Strong Buy) have also advanced and reached a 52-week high of $30.48 on November 14. With a robust portfolio, a strong earnings surprise history, increased guidance and a year-to-date return of 45.7%, Myriad Genetics offers an attractive investment opportunity. Excellent Quarter On November 5, Myriad Genetics reported fiscal first-quarter earnings per share of 36 cents, beating the Zacks Consensus Estimate by 12.5% and the year-ago earnings by 24%. The company has now delivered positive earnings surprises for 7 straight quarters with an average beat of 9.1%. Revenues increased 21% year over year to $133.4 million, beating the Zacks Consensus Estimate of $130.0 million. Myriad's two businesses - Molecular diagnostic testing and Companion diagnostic services - recorded revenues of $127.3 million (up 22% year over year) and $6.2 million (down 4.6%), respectively. The company's flagship product, Bracanalysis (representing 78.7% of total revenues during the quarter), has been growing robustly over the past few quarters on the back of increasing penetration in both the Oncology and Women's Health markets. In the last reported quarter, this product recorded a 17% jump in revenues to $105 million. In addition, revenues derived from Colaris and Colaris AP, which assess a patient's risk of developing hereditary colorectal and uterine cancers, increased 26% to $12.1 million. Moreover, the company is enjoying a strong and diversified pipeline across six major medical specialties. In the last earnings call, Myriad's announcement of its expected launch of molecular diagnostic test Melapath in 2013 has acted as another impetus in driving the share price higher. Melapath is expected to play a ground-breaking role in determining whether a skin biopsy is malignant or benign. The company is confident about the potential of Melapath, which has achieved 95% accuracy in predicting which suspicious skin lesions are malignant and has an anticipated market opportunity of $400 million a year in the US. Furthermore, the company has progressed in receiving reimbursements for the BART (Brac Analysis Large Rearrangement Technology) test. The Noridian Administrative Services announced that Medicare would reimburse the test for patients with a personal history of breast or ovarian cancer from October 1, 2012 onwards. Myriad has already started receiving huge number of testing requests. Upbeat Guidance Myriad Genetics raised its outlook for fiscal 2013. The company now expects revenues between $570 million and $585 million (previous guidance was $550-$565 million), reflecting growth of 15-18%. The raised guidance is primarily based on an improved outlook for the Molecular Diagnostics segment, which is expected to gross $545 million to $557 million in the fiscal year. The guidance for the Companion diagnostic remained unchanged at $25 million to $28 million. Earnings per share for the fiscal year is likely to be in a range of $1.50 to $1.55, up from the previous range of $1.44-$1.48. Rising Earnings Estimates Over the past 30 days, the Zacks Consensus Estimate for 2012 has gained 5.4% to $1.55 per share, thanks to upward revisions from all 13 estimates. This represents year-over-year growth of about 18.9%. Meanwhile, the Zacks Consensus Estimate for 2013 is up 4.7% to $1.77 on positive revisions from 12 of 13 estimates. This indicates growth of about 14.7% year over year. Chart Reflects Strength Myriad's price performance has been reasonably strong with the chart showing an upward trend. Following the release of its first quarter results, the stock showed a steep uptrend and is currently trading above both its 50- and 200-day averages. A series of earnings beats, rising estimates and upbeat growth prospects make Myriad worth considering as a momentum stock. Headquartered in Salt Lake City, Utah, Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. So far, Myriad has launched nine commercial molecular diagnostic products, including five predictive medicine (designed to assess an individual's risk for developing a disease later in life), three personalized medicine (identification of a patient's probability of responding to drug therapy) and one prognostic medicine (assess a patient's risk of disease progression and recurrence) product. Myriad has a market capitalization of $2.45 billion. Want More of Our Best Recommendations? Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential. Learn More>>

Read more from the original source:
Myriad Genetics - Momentum

Earnings momentum for Myriad Genetics (MYGN) has been on the rise ever since this molecular diagnostic company released strong fiscal first-quarter results earlier this month that included an upbeat guidance. Shares of this Zacks #1 Rank (Strong Buy) have also advanced and reached a 52-week high of $30.48 on November 14. With a robust portfolio, a strong earnings surprise history, increased guidance and a year-to-date return of 45.7%, Myriad Genetics offers an attractive investment opportunity.

Excellent Quarter

On November 5, Myriad Genetics reported fiscal first-quarter earnings per share of 36 cents, beating the Zacks Consensus Estimate by 12.5% and the year-ago earnings by 24%. The company has now delivered positive earnings surprises for 7 straight quarters with an average beat of 9.1%.

Revenues increased 21% year over year to $133.4 million, beating the Zacks Consensus Estimate of $130.0 million. Myriad's two businesses - Molecular diagnostic testing and Companion diagnostic services - recorded revenues of $127.3 million (up 22% year over year) and $6.2 million (down 4.6%), respectively.

The company's flagship product, Bracanalysis (representing 78.7% of total revenues during the quarter), has been growing robustly over the past few quarters on the back of increasing penetration in both the Oncology and Women's Health markets. In the last reported quarter, this product recorded a 17% jump in revenues to $105 million. In addition, revenues derived from Colaris and Colaris AP, which assess a patient's risk of developing hereditary colorectal and uterine cancers, increased 26% to $12.1 million.

Moreover, the company is enjoying a strong and diversified pipeline across six major medical specialties. In the last earnings call, Myriad's announcement of its expected launch of molecular diagnostic test Melapath in 2013 has acted as another impetus in driving the share price higher. Melapath is expected to play a ground-breaking role in determining whether a skin biopsy is malignant or benign. The company is confident about the potential of Melapath, which has achieved 95% accuracy in predicting which suspicious skin lesions are malignant and has an anticipated market opportunity of $400 million a year in the US.

Furthermore, the company has progressed in receiving reimbursements for the BART (Brac Analysis Large Rearrangement Technology) test. The Noridian Administrative Services announced that Medicare would reimburse the test for patients with a personal history of breast or ovarian cancer from October 1, 2012 onwards. Myriad has already started receiving huge number of testing requests.

Upbeat Guidance

Myriad Genetics raised its outlook for fiscal 2013. The company now expects revenues between $570 million and $585 million (previous guidance was $550-$565 million), reflecting growth of 15-18%. The raised guidance is primarily based on an improved outlook for the Molecular Diagnostics segment, which is expected to gross $545 million to $557 million in the fiscal year. The guidance for the Companion diagnostic remained unchanged at $25 million to $28 million. Earnings per share for the fiscal year is likely to be in a range of $1.50 to $1.55, up from the previous range of $1.44-$1.48.

Rising Earnings Estimates

Read more:
Myriad Genetics (MYGN): Zacks Rank Buy

SAN MARINO, Calif.--(BUSINESS WIRE)--

Viral Genetics, Inc. (Pink Sheets:VRAL) today announced it will change its name to VG Life Sciences, Inc. and implement a 1-for-600 reverse split of its common stock. The name change and the reverse stock split are expected to be become effective on or about November 26, 2012, pending review and acceptance by FINRA. Both the name change and the reverse stock split were approved by a majority of the Companys shareholders after recommendation by the Board of Directors of the Company. This corporate action and name change followed an earlier increase to authorized common stock of the Company in October 2012 and changes to the terms of the Companys Series A Preferred Shares in August 2012.

The Board of Directors took these actions for several important reasons, said Haig Keledjian, Viral Genetics CEO. The primary reason is the strength of our science and our intellectual property portfolio. We have worked long and hard to build our IP and to begin moving some of the molecules and compounds from our basic science and discovery efforts into clinical trials at prestigious medical institutions. In order to accelerate our movement down this path we are revamping our corporate structure into a more credible format. This new capital structure gives us more credibility with potential business partners, institutional funding sources, and the new executive talent that we are seeking to hire as we move from a basic research-oriented company and develop our capabilities as an operating drug development business.

The name change reinforces our evolution from a purely R&D focus, continued Mr. Keledjian. VG Life Sciences, Inc. more accurately depicts our intellectual property and the business focus which is broader than pharmaceuticals and now reaches into biofuels, agricultural technology and other high-growth industries.

As a significant shareholder of the Company and someone who has devoted more than 15 years of my life to its success, my intention going forward is to build value on this newly established base, concluded Mr. Keledjian.

Interim Increase to Authorized Common Share Capital

In October 2012, the Board recommended and a majority of shareholders approved an increase to the authorized common stock of the Company, increasing the authorized common stock from 1,500,000,000 common shares to 3,000,000,000 common shares. At the time of the increase, there were approximately 1,500,000,000 common shares issued and outstanding with additional share issuance obligations due. The Board believed an increase to authorized common shares was required in order to meet these interim obligations during the FINRA review period for the reverse stock split. Without this increase, the Company would have defaulted in meeting those obligations.

Debt Settlements and Payments

In connection with the increase to authorized common stock of the Company, the Company recently settled portions of certain outstanding debts.

On September 14, 2012, the Company agreed to amend the terms of certain outstanding convertible debentures and unsecured advances (the 2012 Debentures) totaling $848,500, representing cash advanced to the Company by an arms-length private investor over the past 18 months. The 2012 Debentures originally allowed the conversion of outstanding principal into shares of common stock at the investors option at varying prices but generally at $0.0025. Because of the decrease in the Companys common stock price and the pending maturity of several of the 2012 Debentures, the investor was unlikely to exchange their debt for common shares, and would likely demand repayment in cash. The Company was not in a position to repay this debt in cash. The Company and the investor agreed to amend the 2012 Debentures, such that the 2012 Debentures will be settled and paid through the issuance of a total of approximately 920 million shares of common stock issuable over the next 12 months, upon the maturity of each portion of the debt, without any further consent required by the investor. The effective conversion price of the issuances is a weighted average price of $0.00092. Under the terms of the underlying 2012 Debentures, the investor may not engage in any conversions of debt to shares including under the amended terms if upon receipt of such shares they would beneficially own an aggregate number of shares greater than 9.99% of the total issued and outstanding common shares of the Company. To date, the Company has paid a total of $55,000 of the amended 2012 Debentures through the issuance of a total of approximately 222 million shares of common stock, leaving $793,500 due and payable through the issuance of an additional approximately 698 million shares of common stock over the next year.

Read more:
Viral Genetics Announces Details of Corporate Restructuring, Including Name Change, Reverse Stock Split and Increase ...

CGD Society - Gene Therapy film - Prof. Adrian Thrasher
In this film, Prof. Adrain Thrasher of the UCL Institute of Child Health, England, talks about the progress that has been made with gene therapy over recent years. He explains that while gene therapy is not currently a long-term alternative to bone marrow transplantation for patients with CGD, it is an option for those who are seriously ill.From:CGDSocietyViews:1 0ratingsTime:04:47More inNonprofits Activism

Read this article:
CGD Society - Gene Therapy film - Prof. Adrian Thrasher - Video

GENETICS 3: GENE THERAPY
GENE THERAPYFrom:drjahn41Views:0 0ratingsTime:01:00More inScience Technology

Originally posted here:
GENETICS 3: GENE THERAPY - Video

Dr. Tsilfidis on XIAP Gene Therapy
XIAP gene therapy is unique madi-in-Canada therapy for retinal disease. Developed by Dr. Catherine Tsilfidis and her colleagues at the University of Ottawa and the Ottawa Hospital Research Institute, the treatment aims to slow cell death in the retina and preserve vision. Promising findings show that the therapy can potentially halt cell death in many conditions including retinitis pigmentosa and retinal detachment, preventing further vision loss. Learn more about XIAP Gene Therapy in this short video interview with Dr. Tsilfidis (1:30 minutes). Footage provided by: Accessible Media Inc. (www.ami.ca)From:FFBCanadaViews:1 0ratingsTime:01:31More inEducation

Read more:
Dr. Tsilfidis on XIAP Gene Therapy - Video

Favorable patent decision involves rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease

Atlanta, Georgia (PRWEB) November 20, 2012

In the companys news yesterday,

Cardium Therapeutics announced it was on the winning side of a patent decision made in Europe. This decision resolved a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease. Cardiums Generx gene therapy candidate, which employs these key methods, is currently in late-stage clinical studies.

Cardiums patent portfolio now includes allowed and issued patents covering its gene therapy approach both in Europe and in the United States, with competing patent applications licensed and pursued by Boston Scientific having been successfully overcome in both Europe and the U.S.

The competing patent applications licensed by Boston Scientific Corporation had been the subject of opposition proceedings in Europe and interference proceedings in the United States, both of which were ultimately resolved in Cardiums favor. After further examining Cardiums case, the European Patent Office approved Cardiums patent application for grant in Europe. Three corresponding U.S. Patents that had been challenged by Boston Scientific Corporation have been affirmed in the favor of Cardium.

Cardium has additional patents and patent applications involving its methods of cardiovascular gene therapy in the U.S., Europe, Russia, and in other parts of the world, and the company recently filed new patent applications involving certain improved techniques for the treatment of heart disease that are currently the subject of a Phase 3 registration trial based in Moscow, which is designed to generate additional safety and effectiveness data for the Russian Federation and other jurisdictions. Generx (alferminogene tadenovec) is intended to stimulate the growth of collateral blood vessels to effectively bypass coronary artery atherosclerotic blockages without the need for surgical procedures or angioplasty and stents. Its safety and effectiveness have been the subject of clinical studies involving more than 650 patients in the U.S., Europe, and elsewhere. Generx has been assigned the trade name Cardionovo for planned commercialization in the Russian Federation. Cardium believes that its Generx clinical database represents the largest and most complete gene therapy dossier and is directed to a major medical indication that is a leading cause of death throughout the developed world.

The resolution of these important reviews of our gene therapy patents, and the consistent decisions in our favor including rulings by the U.S. courts of appeal, underscore the value of our patent portfolio, which we believe reflects a breakthrough approach to the treatment of coronary heart disease, stated Dr. Tyler M. Dylan-Hyde, Chief Business Officer and General Counsel of Cardium Therapeutics.

Recently-published findings demonstrate that Cardiums innovative technique employing transient cardiac ischemia can be used to dramatically enhance gene delivery and transfection efficiency after one-time intracoronary administration of adenovector in mammalian hearts. Two consecutive but brief periods of coronary artery occlusion combined with co-administration of nitroglycerin increased both adenovector presence (measured by PCR) and transgene expression (assessed by luciferase activity) by over two orders of magnitude (>100 fold) in the heart, as compared to prior intracoronary artery delivery methods.

The research results published in Human Gene Therapy Methods extend those findings and demonstrate that Cardiums new technique for adenovector gene delivery in the heart can be used to dramatically boost adenovector delivery. By enhancing uptake even in patients with less severe forms of disease and ischemia, it would be expected to reduce response variability and allow for the potential treatment of patients with a broader range of associated coronary artery disease. The new treatment protocols for Cardiums recently-initiated ASPIRE clinical study have been developed to use this improved knowledge about induced transient ischemia techniques to enhance the non-surgical, catheter-based delivery of Generx to the heart.

View post:
MissionIR News - Cardium Therapeutics Wins IP Protection for Cardiovascular Gene Therapy

Video 7 - November 14, 2012 - Adult Stem Cells Progress.wmv
Breif interview of my progress with Multiple Sclerosis with Adult Stem Cell therapy after my experience with Tysabri, Gilenya and Ampira failed.From:MSajourneyfromwithinViews:1 0ratingsTime:04:21More inEducation

View post:
Video 7 - November 14, 2012 - Adult Stem Cells Progress.wmv - Video

NeoStem - A Global Cell Therapy Company
From:NeoStemIncViews:5 0ratingsTime:01:53More inScience Technology

Go here to see the original:
NeoStem - A Global Cell Therapy Company - Video

Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v
http://www.newininstitute.com.au PRP Therapy was chosen instead of a Hair Transplant to treat an area of hair loss in a female. 2 month comparison Before and After photos show a highly successful outcome. Note that continued hair growth will occur over the coming months. Another procedure will need to be performed at around the peak period: 12-18 months when growth begins to slow. Newin Institute has uniquely developed processes and protocols for PRP and Adipose Stem Cell Therapy.From:Rhett BosnichViews:0 0ratingsTime:00:55More inScience Technology

Read the original post:
Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v - Video

What Are Stem Cells and Stem Cell Therapy Stemenhance
http://www.stemcellproduct.net This video gives you the definition, facts, and understanding on what are stem cells, that there are two of them embryonic and adult stem cells, how they work and the uses of stem cell when the tissue is affected in your body and how messengers signal the bone marrow to release adult stem cells to help in the repair of the injured tissue. Why this information is exciting for me to do a video is because I see stemcells as the best way of how to produce optimal health in your body. The way I look at it is that optimal health equals the number of healthy cells in your body and the only way the body repairs a damaged area is by creating and sending adult stem cells to that area. That #39;s why I #39;m introducing a stem cell product from a nutrition company who patented a stem cell enhancer which supports the release of adult stem cells. What will also excite you too is that Stemtech (the stemcell company) has also come out with two other products that will also optimize the circulation of these stem cells and other nutrients and aid in the ability for them to move and migrate into the affected tissue where they can transform and duplicate into fresh, healthy new cell tissue. So in my eyes having products like these will help anyone in my pursuit of health and wellness. I know it #39;s helping me strengthening my cells in my body after being diagnosed with chronic fatigue syndrome 20 plus years ago because I know how important nutrition and cell help to gain my ...From:Jennifer MarksViews:1 0ratingsTime:06:37More inHowto Style

See the original post:
What Are Stem Cells and Stem Cell Therapy Stemenhance - Video

SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate product usingmice models for testing.Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study.

The results of Regen's study will provide the safety profile data required for filing of anInvestigational New Drug (IND) application for the product with the US Food and Drug Administration .Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.

HemaXellerate offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions."Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."

Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at http://www.regenbiopharma.com.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks

Read the original:
Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy

ZÉLL-V Sheep Placenta Anti Aging Satisfied Customer - Qiao Ling
http://www.zell-v.com We specialise in cell therapy products for anti aging. we are supported by an international medical board of practitioners, biologist and wellness professionals.From:zellvsheepplacentaViews:5 0ratingsTime:01:56More inHowto Style

Continue reading here:
ZÉLL-V Sheep Placenta Anti Aging Satisfied Customer - Qiao Ling - Video

The Irish Times - Monday, November 19, 2012

CLAIRE O'CONNELL

Could a particular type of adult stem cell offer a useful therapy for diabetes? An EU-funded project being led by NUI Galway hopes to find out.

The 6 million Reddstar project will assess whether the stem cells can tackle glucose levels and various complications of diabetes, including diabetic ulcers and eye, nerve, heart and kidney and bone damage.

The approach centres on a specific adult stem-cell population owned by Orbsen Therapeutics, a spin-out from the Science Foundation Ireland-funded Regenerative Medicine Institute (Remedi) at NUI Galway.

Initially, the project will develop ways to grow the bone-marrow-derived stem cells in a way that is useful for trials, according to company co-founder and Remedi director Prof Tim OBrien.

The cells will then be tested in several preclinical models of diabetic complications at centres in Galway, Belfast, Munich, Berlin and Porto.

Then the plan is to select one complication for which the adult stem cells will be assessed in human trials in Denmark.

The three-year EU funding will support nine jobs in Ireland, five of which will be in Orbsen Therapeutics, according to CEO Brian Molloy, who says the project should help to build Irelands status as a hub for cell therapy development and commercialisation.

Whilst wins such as the Reddstar programme are fantastic for us, we need to continue to develop and advance our product, he says.

Visit link:
NUI Galway to lead €6m research project into stem cell therapy for diabetes

For Dr. Robert Janson-Mller, the science of fresh cell therapy is in his blood.

His grandfather, Dr. Philipp Janson was one of the few doctors who introduced the treatment in Germany. His father, Dr. Wolfgang Janson-Mller continued the work that was eventually passed on to him.

He was exposed to the revolutionary world of fresh cell therapy early on in life. The treatment uses live young cells from a donor animal like sheep to help regenerate damaged cells in the body. Dr. Mller practically grew up in his grandfather and father's clinic where he met the former's patients, some of whom still go to him for their regular treatments.

''A child always wants to grow up like his father and do the same thing. My father left it open for me. He told me I could do whatever I want, the same thing I am doing now for my daughter. I'm also head of a clinic in Munich. This is what I do besides cell treatment. We have a family practice. That is my main job,'' shares the 46-year-old German doctor who recently visited the Philippines to acquaint Filipinos with the science of fresh cell therapy.

Dr. Mller, who owns a fresh cell therapy laboratory and works as head doctor of Med Activ clinic in Munich, says that despite the growing market for it in America and Asia, there are only five doctors in Germany practicing the science. The treatment is known to deter degenerative diseases such as arthrosis, rheumatism and neurological disorders such as multiple sclerosis. But it is most popular as an anti-aging treatment. Recently, it has also been used to treat children with autism and Down syndrome.

Yet, Dr. Mller points out that fresh cell therapy is not a miracle cure for aging or these diseases. Some bodies accept the treatment while some don't. And, it doesn't treat every disease known to mankind.

Nevertheless, patients from all over the world still flock to his private clinic at the Prinzregent Hotel in Edenkoben, Germany to avail themselves of the treatment, which does not come cheap. One session would cost about $12,000 or R624,000.

''I don't treat patients with cancer, tuberculosis, AIDS, or those who are pregnant. We don't treat patients with acute inflammations like appendicitis. Aside from that, I need to see if it makes sense. If I don't see a possibility, I say no,'' he explains.

In this 60 Minutes interview, Dr. Mller shares how fresh cell therapy really works and how it can take more than just one, two, 20, 60 or even 100 treatments to get it right. Some may start as young as eight months old or continue the treatment at 99 years old. This just proves that a patient is never too young nor too old for this revolutionary treatment. (Angelo G. Garcia)

STUDENTS AND CAMPUSES BULLETIN (SCB): A lot of people are confused about the difference between stem cell and fresh cell therapy.

Read the original post:
The cell therapist